EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
BIO-Europe 2015 BIO EBD Group
Share/Follow Us
Share this:
Follow this event:

BIO-Europe® 2016 Program Overview

Previous event program

www.ebdgroup.com/bioeurope/program
Sunday, November 1, 2015
16:00–18:30
Munich Welcome Event at the Bier & Oktoberfest Museum

Munich Welcome Event at the Bier & Oktoberfest Museum
Sunday, 16:00–18:30

Bier & Oktoberfest Museum
Sterneckerstr. 2
80331 Munich (map)

BioM and Medigene welcome you to the Bier & Oktoberfest Museum in Munich's oldest historic town house dating back to the year 1340. Deepen your insight into the world of beer by enjoying the historical chambers with a "Brotzeit" (traditional snack) and a variety of beers from one of Munich's breweries.

This evening event is fully booked! We are sorry!

Sponsored by:
bio-mbio-m MedigeneMedigene BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Munich Welcome Event at the Bier & Oktoberfest Museum

This evening event is fully booked.

Bier & Oktoberfest Museum
Sterneckerstr. 2
80331 Munich (map)

Sponsored by BioM and Medigene

19:00–21:30
Welcome Reception

Sunday, 19:00–21:30

You will be able to pick up your name badge at the welcome reception.

Since 1893 this magnificent building has been a financial center, from the Bavarian State Bank to HVB. It was completely renovated in the last 20 years and decorated with changing exhibitions of contemporary art to serve as an extraordinary event venue.

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
HVB Forum

All BIO-Europe attendees are cordially invited to join us for a Welcome Reception.

HVB Forum
Kardinal-Faulhaber-Straße 1
80333 Munich (map)

Monday, November 2, 2015
07:45
Level 0, Foyer
07:45
Level 0, Hall B1
Exhibition opens and Continental Breakfast
09:00–10:30
Parallel Workshops
The evolving landscape of China's pharmaceutical industry

Monday, 09:00–10:30
Level 0, Room 2

China's pharmaceutical industry has grown at an unprecedented speed along with its booming economy. This has fueled much warranted excitement (and occasionally unfounded fantasies). Today, many opportunities in China are generating global impact in multiple dimensions: market sales, new innovations, talent pools, R&D outsourcing, public and private source of capitals and entrepreneurial initiatives. It was against this backdrop that major drug players ventured to this once mysterious nation, for pharmaceutical sales, R&D expansion and venture investment. Going forward China is poised to be the second largest pharmaceutical market. What are the drivers to sustain the continued growth? Will "Innovated in China" get any closer in replacing "Made in China"? What are the continued challenges and opportunities in capturing the growing opportunities in this huge land?

Moderator:
Darren Ji – Global Head and VP, Roche Partnering Asia and Emerging Markets, Roche

Panelists:
  • Jing Lou – President, Chairman, Co-Founder and CEO, 3SBio
  • Greg B. Scott – Founder and Chairman, ChinaBio® Group
  • Jimmy Wei – Venture Partner, KPCB China
  • Dan Zhang – Founder, Chairman and CEO, Fountain Medical, China
  • James J. Zhu – Partner, Jun He Law Offices
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Microbiome and human health: From understanding to intervention

Monday, 09:00–10:30
Level 0, Room 4

The gut microbiome makes up by far the largest number of cells in the human body. It is the most researched and best-known human symbiotic community. A healthy microbiome sets a person up for a healthy life; an imbalance (dysbiosis) can contribute to a range of diseases. This panel will discuss how this tipping-point from correlation (between diseases and dysbiosis) to causation (how microbiota-altering substances and habits contribute to disease) is understood and how the exponential growth of microbiome research can be translated into powerful new diagnostic and therapeutic products.

Moderator:
Eric de La Fortelle – Venture Partner, Seventure

Panelists:
  • Herve Affagard – CEO, MaaT Pharma
  • Joël Doré – Research Director, INRA
  • Marie Lindner – Global Program Head, Strategic Partnerships Team, Novartis
  • Mark Offerhaus – CEO, Micreos
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Opportunities at the intersection of animal and human health

Monday, 09:00–10:30
Level 0, Room 3

The line between animal and human health is a fluid one. Diseases jump the barrier on a regular basis, leading to virulent epidemics, such as the recent Ebola outbreak. Animals fall ill with the same diseases as humans, from cancer to the common cold. However, therapies can prove equally flexible, serving as springboards for treatments in either population. As we become more aware of the interconnections between human and animal health, the potential for therapies that can bridge the two sectors becomes more obvious. The animal health market is a growing billion dollar industry with tremendous potential for retasking human therapies, funding opportunities for animal health companies and typically a business and regulatory strategy which gets products to market much quicker. However, while growth in the animal health market continues, business, financial and regulatory considerations require a different analysis than the human health market. This panel will explore the fluid boundary between animal and human health and the possibilities available to biotech companies which bridge the two worlds.

Moderator:
Diane Romza-Kutz – Partner, Thompson Coburn

Panelists:
  • Alan Bell – Chairman, Parnell, Animal Health
  • Michael Donabedian – Director, Global Research and Medical Division, Vetoquinol
  • Rustom Masalawala – Senior VP, International Business Development, Jaguar Animal Health
  • Peter Opdam – Director, Business Development Europe, MSD Animal Health
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45–12:30
Level 0 + 1, Room 1 (Auditorium)
Welcome and Opening Plenary Discussion
Welcome
Welcome and Opening Remarks

Monday, 10:45–11:30
Level 0 + 1, Room 1 (Auditorium)

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Franz Pschierer – State Secretary in the Bavarian Ministry for Economic Affairs and Media, Energy and Technology
  • Horst Domdey – Managing Director, BioM
  • David Thomas – Director, Industry Research and Analysis, Biotechnology Industry Organization (BIO)
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Opening Plenary Discussion
How big can be small

Monday, 11:30–12:30
Level 0 + 1, Room 1 (Auditorium)

Moderator:
Mark Edwards – Managing Director, BioScience Advisors

Panelists:
  • John Glasspool – Executive VP, Head, Corporate Strategy and Customer Operations, Baxalta
  • Bahija Jallal – Executive VP, AstraZeneca; Head, MedImmune
  • Simon Sturge – Chief Operating Officer, Merck Healthcare
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Moderator:
Mark Edwards Mark Edwards
Managing Director
BioScience Advisors

Speakers:
John Glasspool Bahija Jallal Simon Sturge
John Glasspool
Executive VP, Head
Corporate Strategy and
Customer Operations
Baxalta
Bahija Jallal
Executive VP
AstraZeneca;
Head, MedImmune
Simon Sturge
Chief Operating Officer
Merck Healthcare
12:30–13:30
Level 0, Exhibition in Hall B1
Level 1, Room 14
Level 1, Restaurant 'Am See'
Luncheon
13:30–18:15
Parallel Panel Discussions
Business Development Track
To IPO or not to IPO: Why biotech companies should go public (or not), and where to do it

Monday, 13:30–14:30
Level 0, Room 4

The decision to go public is riddled with both risk and reward. The number of companies that go through IPOs each year has long been an indication of wider industry health, as well as an appealing exit for investors. But is this still true today? What are the motivations and the pros and cons of going public for a biotech company? How can the process be managed to ensure a smooth transition both internally for the company as well as with investors? With the trend of European companies going public in the US, can and should incentives be developed to make European stock markets more appealing to home grown talent? Join a discussion with business leaders and representatives from stock exchanges and VCs experienced in navigating the divide between public and private.

Moderator:
Peter Homberg – Partner, Dentons

Panelists:
  • Konrad Glund – CEO, Probiodrug
  • Brian Hagerty – Senior Director, Capital Markets, NYSE
  • Christian Hodneland – Managing Director, William Blair & Company
  • Olivier Litzka – Partner, Edmond de Rothschild Investment Partners
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Alliance management

Monday, 14:45–15:45
Level 0, Room 4

Alliances have never been more important for healthcare bottom lines, but getting the deal done is only the beginning of an even more important process: managing the expectations, personalities and progress of the partnership. Rather than sit back and let the collaboration unwind, these relationships can only blossom if challenges and working issues that arise are anticipated and structures are in place to ensure varying stresses are dealt with effectively. Alliance managers from leading pharma will tackle the importance of internal team alliance training, the role of organizational culture differences and adopting a proactive approach to partnership implementation.

Moderator:
Mark Archer – Global Head of Business Development, inVentiv Health

Panelists:
  • Patrick Benz – Senior Director Alliance Management, Johnson & Johnson Innovation
  • Alistair Dixon – Senior Director, Alliance Management, Takeda
  • Shaun Grady – VP, Strategic Partnering and Business Development, AstraZeneca
  • Jan Nilsson – CEO, NeuroVive Pharmaceutical AB
  • James O'Mara – Senior VP, Corporate Development, Ironwood Pharmaceuticals
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
VC involvement in external innovation strategies

Monday, 16:00–17:00
Level 0, Room 4

External innovation provides new avenues to add products to pharma pipelines but also requires a significant investment of time and resources. Pharma, academia, biotech and venture capital each bring something unique to the collaborations that are essential to these models, but VCs occupy a unique position that allows them to bridge the separate worlds of business and research. Join these panelists as they discuss relationship design between strategic pharma partners, portfolio companies and the VCs whose contribution extends beyond financial involvement.

Moderator:
Hubert Birner – Managing Partner, TVM Life Science Management Inc.

Panelists:
  • Darren Carroll – Senior VP, Corporate Business Development, Eli Lilly and Company
  • Stuart Collinson – CEO, Tioga Pharmaceuticals and Partner, Forward Ventures
  • Corinne Savill – Head, Pharma Business Development & Licensing, Novartis
  • Lesley Stolz – Senior Director Transactions, Johnson & Johnson Innovation
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Alternative financing

Monday, 17:15–18:15
Level 0, Room 4

It is said necessity is the mother of invention, and that applies to the funding of innovation as much as to any situation MacGyver might find himself in. What are the alternatives to traditional debt and equity? Developments such as project financing can bring to the table new groups such as patient groups and disease organizations, especially those financing rare diseases. How do these new players contribute to the continuum of life science financing? What alternative instruments are available for those outside of the rare disease space and what innovations are later stage funders bringing to the table? For biotech companies, what considerations need to be taken with these and other sources of alternative finance?

Moderator:
David Schulman – Partner, Corporate, Life Sciences, Dechert, LLP

Panelists:
  • Paul Hadden – Managing Director, HealthCare Royalty Partners
  • Regina Hodits – Partner, Wellington Partners
  • Elias Papatheodorou – Acting CEO, Genkyotex
  • Ignacio Pino – CEO, CDI Labs
  • Jesper Wiklund – Managing Director, Europe, Oberland Capital
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Spotlight Track
Global vaccine outlook

Monday, 13:30–14:30
Level 0, Room 2

The worldwide vaccine market continues to grow as countries try to keep the threat of infectious diseases at bay. Pharma companies and government agencies from the United States and Europe will explore the need for cross-border collaborations to efficiently develop new vaccines, address the current international regulatory environment, and highlight opportunities for vaccine development, supply, pricing, procurement and dissemination to ensure access is available when needed.

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • David Gancberg – Innovative Tools, Technologies and Concepts in Health Research, Directorate-General, DG Research and Innovation, Directorate Health, European Commission
  • Elmar Maier – Senior Business Advisor, CureVac AG
  • Niranjan Y. Sardesai – Chief Operating Officer, Inovio Pharmaceuticals
  • Russell Wilson – Senior VP, Business Development, Novavax, Inc.
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
The changing landscape for reimbursement in Europe

Monday, 14:45–15:45
Level 0, Room 2

As European governments continue to struggle with healthcare budgets, the pressures on new drug pricing and reimbursement continue to intensify. Exacerbating this is growing concern about the cost of new therapies in oncology and other areas. What steps are governments taking to address their concerns (whether misplaced or not) about rising drug costs? How is Health Technology Assessment being used (or abused) in determining reimbursement and setting prices? How is HTA being supplemented by other government policies in the pricing and reimbursement space? And finally, how will EU policies with respect to biosimilars affect the market for new products? This panel explores these and related questions.

Moderator:
Joseph Damond – Senior VP, International Affairs, Biotechnology Industry Organization (BIO)

Panelists:
  • Richard Bergström – Director General, EFPIA
  • Alexander Natz – Secretary General, EUCOPE
  • David Talbot – Senior Director, International Government Affairs, Eli Lilly and Company
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bringing rare cancer therapies to market

Monday, 16:00–17:00
Level 0, Room 2

Rarity (incidence of < 5/100,000) creates a number of hurdles in creating effective, affordable cancer treatments. Aside from the logistical difficulties of running clinical trials with extremely small populations, rarity also impacts the process of market authorization and securing reimbursement. Within the EU especially, navigating multiple national regulatory and reimbursement bodies can be overwhelming for clinicians, patients and companies. Join representatives from industry and public organizations as they examine potential solutions and the collaborations needed to get therapies to patients.

Moderator:
Mike Riley – VP and General Manager, Catalent Biologics

Panelists:
  • Niels Emmerich – Senior Director, Global Head Search and Evaluation, Oncology, AbbVie
  • Sarah Holland – Head of Europe, External Science and Partnering, Sanofi
  • Konstantin Petropoulos – Director, Business Development, MorphoSys
  • Jeremy Springhorn – Partner, Corporate Development, Flagship Ventures
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Focus on diabetes

Monday, 17:15–18:15
Level 0, Room 2

Moderator:
Karin Hehenberger – CEO and Founder, Lyfebulb

Panelists:
  • Juliane Bernholz – Lead International Diabetes Partnering, Sanofi
  • Brian Bloomquist – Senior Director, Diabetes Search and Evaluation, Eli Lilly and Company
  • Vered Caplan – President and CEO, Orgenesis, Inc.
  • Karin Conde-Knape – VP, Cardiovascular and Metabolism Scientific Innovation, Johnson & Johnson Innovation
  • Tomas Landh – Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Advanced Therapies


Advanced Therapies
Immuno-oncology: Combination therapies

Immuno-oncology: Combination therapies
Monday, 13:30–14:30
Level 0, Room 3

As new advances in immuno-oncology evolve, we are observing unique combination therapies and the formation of atypical partnerships. This panel will examine collaborations among key players, how they are treating an array of cancers and how the industry is leveraging the advances in this sector.

Moderator:
Beatrice Gerard – VP, Advisory Services, Strategic Drug Development, Quintiles

Panelists:
  • Michel Detheux – Co-Founder and CEO, iTeos Therapeutics
  • Iain Dukes – Senior VP, Business Development and Licensing, MSD
  • Philippe Lopes-Fernandes – Senior VP, Head, Global Licensing and Business Development, Merck Serono
  • Mohamed Ragab – VP, Head, Oncology Search and Evaluation, Business Development, Bristol-Myers Squibb
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Cell-based therapies for cancer

Cell-based therapies for cancer
Monday, 14:45–15:45
Level 0, Room 3

With all of the exciting developments in this field, this session will get past the hype and discuss the practical issues that need to be addressed in order for the promises of treatments to become reality. Hear company executives share their strategies to innovate, fund, partner, and commercialize the cell-based technologies that may truly disrupt healthcare.

Moderator:
Mike Ward – Global Director of Content, Informa Pharma Insights

Panelists:
  • Philippe Duchateau – Chief Scientific Officer, Cellectis
  • Michael Leek – Chief Executive, TC BioPharm
  • Dolores J. Schendel – Chief Scientific Officer, Executive Board, Medigene AG
  • Jason Slingsby – Head, Business Development, Oxford BioMedica
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Quest for cures: New business models for new therapies

Quest for cures: New business models for new therapies
Monday, 16:00–17:00
Level 0, Room 3

With the advances being made in cell and gene therapy come greater opportunities and challenges in developing and commercializing cures. How are these potentially transformative technologies providing new partnering opportunities for emerging companies and established pharmacos? What strategies do companies have to incorporate cell and gene therapies into their pipelines? How are companies working together to bridge the gap from R&D to commercialization? Hear from leading biotech and pharma companies that are building out their capabilities in gene and cell therapies.

Moderator:
Morrie Ruffin – Managing Partner, Adjuvant Partners

Panelists:
  • Frank Borriello – VP, Head of Search and Evaluation, Global Business Development, Baxalta
  • Jennifer A. King – VP, Business Development, Intellia Therapeutics, Inc.
  • Peter Mooney – Medical Scientific Liaison Director, Global Medical Affairs, Gene Therapy, Rare Diseases, GlaxoSmithKline
  • Peter Seufer-Wasserthal – VP, Business Development, Intrexon Corporation
  • Guillaume Vignon – Director, Business Development Oncology and Immuno-Oncology, Global Licensing and Business Development, Merck Serono
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:30–18:30
One-to-one Meetings ►
13:15–18:30
Pharma Presentations
13:15–13:30
Novo Nordisk

Novo Nordisk
Monday, 13:15–13:30
Level 0, Room 5

Speaker:
  • Tomas Landh – Innovation Sourcing VP, Senior Principal Scientist
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:30–13:45
Roche

Roche
Monday, 13:30–13:45
Level 0, Room 5

Speaker:
  • Darren Ji – Global Head and VP, Roche Partnering Asia and Emerging Markets
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:45–14:00
Genentech

Genentech
Monday, 13:45–14:00
Level 0, Room 5

Speaker:
  • Don O'Sullivan – Associate Director, Global Head Immunology and Infectious Disease, Genentech Partnering
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Takeda Pharmaceutical Company Ltd.

Takeda Pharmaceutical Company Ltd.
Monday, 14:00–14:15
Level 0, Room 5

Speaker:
  • Jane Atkins – Director, Search and Evaluation Europe
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Boehringer Ingelheim Licensing

Boehringer Ingelheim Licensing
Monday, 14:15–14:30
Level 0, Room 5

Speaker:
  • Paola Casarosa – Corp. VP, BD&L/Prescription Medicines
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Eli Lilly and Company

Eli Lilly and Company
Monday, 14:30–14:45
Level 0, Room 5

Speaker:
  • Johnston Erwin – VP, Corporate Business Development
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:45–15:00
AbbVie

AbbVie
Monday, 14:45–15:00
Level 0, Room 5

Speaker:
  • John Poulos – VP, Head of Licensing and Acquisitions
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:00–15:15
MSD

MSD
Monday, 15:00–15:15
Level 0, Room 5

Speaker:
  • Reza Halse – Head, MSD European Innovation Hub
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bayer HealthCare Pharmaceuticals

Bayer HealthCare Pharmaceuticals
Monday, 15:15–15:30
Level 0, Room 5

Speaker:
  • Berthold Hinzen – VP and Head, Global Business Development and Licensing General Medicine
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:30–15:45
Baxalta

Baxalta
Monday, 15:30–15:45
Level 0, Room 5

Speaker:
  • Claude Knopf – VP, Business Development and Licensing
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Merck Serono, a division of Merck KGaA

Merck Serono, a division of Merck KGaA
Monday, 15:45–16:00
Level 0, Room 5

Speaker:
  • Philippe Lopes-Fernandes – Senior VP, Head of Global Licensing and Business Development
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bristol-Myers Squibb

Bristol-Myers Squibb
Monday, 16:00–16:15
Level 0, Room 5

Speaker:
  • Donnie McGrath – VP, Search and Evaluation, Business Development
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Johnson & Johnson

Johnson & Johnson
Monday, 16:15–16:30
Level 0, Room 5

Speaker:
  • Mike Grissinger – VP, Corporate Development
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:30–16:45
Novartis

Novartis
Monday, 16:30–16:45
Level 0, Room 5

Speaker:
  • Markus Kalousek – BD&L Search and Evaluation Franchise Head, Immunology, Dermatology, Transplant, Nephrology
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:45–17:00
Amgen

Amgen
Monday, 16:45–17:00
Level 0, Room 5

Speaker:
  • Ray Barlow – Executive Director, Transactions
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:00–17:15
AstraZeneca

AstraZeneca
Monday, 17:00–17:15
Level 0, Room 5

Speaker:
  • Shaun Grady – VP, Strategic Partnering and Business Development
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:15–17:30
BioVentureHub

BioVentureHub
Monday, 17:15–17:30
Level 0, Room 5

Speaker:
  • Magnus R. Björsne – CEO, Executive Director, AZ BioVentureHub AB
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:30–17:45
Sanofi

Sanofi
Monday, 17:30–17:45
Level 0, Room 5

Speaker:
  • Sarah Holland – Head, Europe Science and Partnering, Sanofi R&D.
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Alexion Pharmaceuticals

Alexion Pharmaceuticals
Monday, 17:45–18:00
Level 0, Room 5

Speaker:
  • Susan Hill – Senior Director, Business Development
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
18:00–18:15
Pfizer

Pfizer
Monday, 18:00–18:15
Level 0, Room 5

Speaker:
  • Ron Newbold – VP, Global Scouting, External R&D Innovation
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
18:00–18:45
Level 0, Hall B1, Booth 91
Champagne reception at EBD Group booth
19:00–22:30
Evening Networking Reception with Buffet-style Dinner
Munich Residenz

Munich Residenz
Residenzstrasse
80333 Munich | (map)

The Munich Residenz served as the seat of government, residence and cultural center of the Bavarian dukes, electors and kings from 1508 to 1918. The largest city palace in Germany, it houses extensive room decorations, art and antiquities from the former royal collections.

18:45–19:15 Shuttle buses depart from the congress center to the evening event.
21:30–22:30 Shuttle buses depart from the evening event to all conference hotels.

Sponsored by:

Sanofi Bavaria
Tuesday, November 3, 2015
07:45
Level 0, Foyer
07:45
Level 0, Hall B1
Exhibition opens and Continental Breakfast
09:00–11:00
Workshop
Innovative funding for SMEs in Europe

Tuesday, 09:00–10:30
Level 0, Room 4

With the shortage of early stage life sciences funding, the role of government in funding the next generation of cures is becoming increasingly important. In 2014, the European Union launched the SME instrument, a multibillion euro funding program dedicated to innovative Small and Medium-sized Enterprises (SMEs) in Europe as part of Horizon 2020. Under this program, a single SME can receive up to EUR 5 million for a project with 100% of the costs reimbursed by the EU. The session will provide an overview of this program and will also introduce other Horizon 2020 programs which are relevant for SMEs.

The session will have three presentations. One presentation will be made by a representative from the EU (European Commission – DG Research and Innovation – Health Directorate). Two European small businesses will then share their experience in leveraging government funding to move their technology towards clinical adoption and commercialization. A last presentation will be made by a representative from the EMA SME office and will introduce the Agency's support programs for SMEs.

Moderator:
Antoine Mialhe – Policy Officer, European Commission DG Research and Innovation Health Directorate – Strategy Unit

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter

Nanomedicine Award Ceremony

Tuesday, 10:30–11:00
Level 0, Room 4

The Nanomedicine Award promotes and rewards excellent new projects in nanomedicine. BIO-Europe is hosting this award ceremony for the second time.

The Award is open to companies, academic and private researchers across the globe. The winners that will present their projects have developed innovative solutions based on nanomedicine that can ultimately change the way diseases are treated or diagnosed and that could provide new tools for physicians and benefits to patients.

Nominations for the Award will be accepted until September 15, 2015. More information can be found at nanomedicine-award.com.

Presenter:
Alexandre Ceccaldi – General Secretary of ETPN (European Technology Platform on Nanomedicine)

BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:00–18:00
Company Presentations ►
08:00–18:30
One-to-one Meetings ►
12:00–13:00
Keynote Plenary Discussion
A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2015

Tuesday, 12:00–13:00
Level 0, Room 5

Moderators:
Anton Gueth – Managing Director, EVOLUTION Life Science Partners
Evonne Sepsis – Founder and Managing Director, ESC Advisors

Panelists:
  • Lubor Gaal – Head, External Innovation and Licensing, Almirall
  • George Golumbeski – Senior VP, Business Development, Celgene
  • Sarah Holland – Head, Europe, External Science and Partnering, Sanofi
  • Tibor Papp – Senior Director, Business Development, Haematology/Oncology/Transplantation, Shire Pharmaceuticals
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:00–14:00
Level 0, Exhibition in Hall B1
Level 1, Room 14
Level 1, Restaurant 'Am See'
Luncheon
13:00–14:00
Restaurant
Seeblick
Special lunch session
What you need to know about the life sciences landscape in Europe

Tuesday, 13:00–14:00

What you need to know about the life sciences landscape in Europe:
A panel of experts weighs in on new investment opportunities and current challenges for life sciences companies on the move.

Join us for an exclusive lunch session with distinguished representatives from Europe and Switzerland discussing the current life sciences and investment environment, and differences in various locations. The panel answers questions like: How location and the ability to raise funds are interconnected? What are the alternatives besides VC? How do you find global partners and what are the best ways to expand your operation in Europe? Hear where VCs see investment opportunities in Europe, what Basel, Switzerland-based companies say about one of Europe's leading life sciences clusters, and hear KPMG's latest findings of their 2015 European Site Selection report for life sciences companies.

This is a Swiss event you can't miss to get first-hand industry insights and to network with peers, potential clients and investors!

REGISTRATION IS REQUIRED! Click here to register ►.

Introduction:
Patrik Frei – CEO, Venture Valuation
Gabriela Guentherodt – Director, BaselArea
André Guedel – Senior Manager, KPMG

Panel discussion:
  • Ulf Grawunder – CEO, NBE-Therapeutics Ltd.
  • Markus Hosang – General Partner, BioMedPartners AG
  • Ravi Sodha – Senior Director, Business Development, Actelion
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter

Hosted by:

Registration is required. Click here to register ►

14:00–15:00
Workshop
Optimizing value: Does your evidence generation plan match your exit strategy?

Tuesday, 14:00–15:00
Level 0, Room 4

Hosted by:
QuintilesQuintiles

Join leaders in clinical development, innovation, and funding as we discuss various exit and commercialization options and the associated best practices necessary to address the evidence and stakeholder requirements common in today's European biotech market.

Moderator:
Laura Marquis – VP and Global Head, Quintiles Emerging Biopharma

Panelists:
  • Stuart Collinson – Partner, Forward Ventures; CEO, Tioga Pharmaceuticals and Executive Chairman, Arcturus Therapeutics
  • Helen Davies – Senior VP and Global Head, Quintiles Therapeutic Strategy
  • Tom Nijhuis – Engagement Leader, Quintiles Advisory Services
  • Simon Read – VP and Head, Innovative Medicines, Grünenthal Group
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:45–18:45
Level 0, Hall B1
Exhibit Hall Hospitality Receptions

Sponsored by:

BioM BioM at Booth 74
Life Science Nord Life Science Nord at Booth 90
Lonza Lonza at Booth 94
Puerto Rico Puerto Rico at Booth 97b
Quintiles Quintiles at Booth 37
19:00–22:30
Evening Networking Reception with Buffet-style Dinner
Löwenbräukeller

Löwenbräukeller
Nymphenburgerstrasse 2
Am Stiglmaierplatz
80335 Munich | (map)

The Löwenbräukeller is a typical Bavarian location in Munich. It opened its doors in 1883, when the use of table linen and napkins as well as electric lighting in the whole building was a sensation. Today, the Löwenbräukeller is managed by Christian Schottenhamel, whose grandfather founded the first Oktoberfest beer tent on the Theresienwiese, a little shack with room for 50 people.

Optional Dress Code: We'd be happy to see many of you in your Dirndl and Lederhosen, a perfect complement to this traditional Bavarian locale!

Sponsored by:

Bayer HealthCare

18:45–19:15 Shuttle buses depart from the congress center to the evening event.
21:30–22:30 Shuttle buses depart from the evening event to all conference hotels.

Wednesday, November 4, 2015
07:45
Level 0, Foyer
07:45
Level 0, Hall B1
Exhibition opens and Continental Breakfast
09:00–12:45
Partnerships in Regenerative Medicine and Advanced Therapies Company Presentations

Partnerships in Regenerative Medicine and Advanced Therapies Company Presentations
Wednesday, 09:00–12:45
Level 0, Room 3
  • Arthrogen
  • U.S. Army Medical Research & Materiel Command
  • apceth GmbH & Co. KG
  • Stemedica International SA
  • Cytonet GmbH & Co. KG
  • Sirona Biochem Corp
  • Fresenius Medical Care Deutschland GmbH
  • PTC Therapeutics, Inc.
  • Gene Signal International SA
  • Oxford BioMedica
  • Green Cross LabCell
  • Organovo
  • Kiadis Pharma
  • MEDIPOST America, Inc.
  • Lacerta Technologies
BIO-Europe® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00–17:00
One-to-one Meetings ►
09:00–13:00 Company Presentations ►
13:00–14:00
Level 0, Exhibition in Hall B1
Level 1, Room 14
Level 1, Restaurant 'Am See'
Luncheon
16:30
Level 0, Hall B1, Booth 62
Closing Reception
Hosted by:
BIO.NRWBIO.NRW
Arrow Up

Follow this event:
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD GmbH
Privacy Policy and Cookies
Terms of Use